Skip to main content
Clinical Trials/NCT06231914
NCT06231914
Recruiting
Not Applicable

Efficacy and Safety of Fractional 1064-nm Picosecond Laser for Facial Skin Tightening

Mahidol University1 site in 1 country30 target enrollmentStarted: December 1, 2023Last updated:
ConditionsLaxity; Skin

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
30
Locations
1
Primary Endpoint
The changes in skin elasticity.

Overview

Brief Summary

The goal of this clinical trial is to learn the efficacy and safety of fractional 1064-nm picosecond laser for facial skin tightening. The main questions it aims to answer are:

  • Efficacy of fractional 1064-nm picosecond laser for facial skin efficacy including the changes in wrinkle, nasolabial fold, skin laxity, and skin elasticity
  • The changes in texture and pore volume using Antera
  • The changes in bioengineering assessment: melanin index, erythema index, sebum level
  • Adverse events Participants will be treated with 3 sessions of fractional 1064-nm picosecond laser (full face 4 passes, vector lines 4 passes), spaced 4 weeks apart. Follow-up visits 1, 3, and 6 months after the last treatments.

Detailed Description

The efficacy and safety of fractional 1064-nm picosecond laser for facial skin tightening in participants aged 40 to 55 years, BMI < 25 kg/m2, and have mild to moderate facial laxity.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Aged 40-55 years
  • BMI \< 25 kg/m2
  • Mild to moderate facial skin laxity using quantitative grading scale (grade 1.5-2.5)

Exclusion Criteria

  • Pregnant or lactation
  • Subjects who have been treated with any kind of energy-based device 6 months prior to the inclusion
  • Subjects who have been injected with botulinum toxin, filler, or platelet-rich plasma on their faces 6 months prior to the inclusion
  • Active skin infections
  • History of hypertrophic scars or keloids

Outcomes

Primary Outcomes

The changes in skin elasticity.

Time Frame: 4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.

The changes in skin elasticity (R0, R2, R5) using Cutometer (%)

The changes in wrinkle.

Time Frame: 4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.

The changes in indentation of wrinkle using Antera (mm3)

The changes in nasolabial fold.

Time Frame: 4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.

The changes in nasolabial fold using Quantificare (mm3)

The changes in skin laxity.

Time Frame: 4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.

The changes in skin laxity using Quantificare (mm3)

Secondary Outcomes

  • The changes in pore volume.(4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.)
  • Adverse events(4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.)
  • The changes in skin texture.(4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.)
  • The change in melanin index and erythema index.(4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.)
  • The change in sebum level.(4 weeks after the first treatment, 4 weeks after the second treatment, during 1, 3, and 6 months after the last treatment.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Woraphong Manuskiatti, M.D.

Prof. Dr.

Mahidol University

Study Sites (1)

Loading locations...

Similar Trials